Post-Marketing Surveillance

Surveillance of Rare Adverse Events Post-Vaccination

Posted on digi By digi

Licensure is not the finish line for safety; it is the start of population-scale learning. Even very large pre-licensure trials are underpowered for events with true incidences of 1–10 per million doses (e.g., anaphylaxis, myocarditis, thrombosis with thrombocytopenia [TTS], Guillain–Barré syndrome). Post-marketing surveillance therefore stitches together multiple streams—spontaneous reports, active healthcare databases, registries, and targeted studies—to detect, assess, and communicate signals. Reviewers look for a plan that links governance (dedicated safety team and decision cadence), methods (passive vs active), thresholds (what constitutes a signal), and evidence (rooted in transparent analytics and case definitions). The Trial Master File (TMF) must make ALCOA obvious: attributable, legible, contemporaneous, original, accurate.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Surveillance of Rare Adverse Events Post-Vaccination

Posted on digi By digi

Licensure is not the end of safety work; it marks the start of population-scale learning. Pre-licensure studies are typically underpowered for events occurring at 1–10 per million doses (e.g., anaphylaxis, myocarditis, thrombosis with thrombocytopenia syndrome [TTS], Guillain–Barré syndrome). Post-marketing surveillance fills that gap by combining passive signals from spontaneous reports with active analyses in electronic health records (EHR) and claims data, plus targeted follow-up and registries. Reviewers expect a plan that connects four pillars: (1) governance (safety team, cadence, decision rights), (2) methods (screening and confirmation), (3) thresholds (what constitutes a “signal”), and (4) evidence (traceable analytics and case definitions). They also expect ALCOA—records that are attributable, legible, contemporaneous, original, and accurate—with audit trails for database cuts and code.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Vaccine Hesitancy and Public Perception Studies

Posted on digi By digi

Post-marketing pharmacovigilance tells you what is happening clinically; hesitancy research explains why people make uptake decisions in the real world. If a region shows slower vaccination despite adequate supply, you need more than doses-delivered dashboards—you need evidence on beliefs, trust, convenience barriers, and rumor dynamics. Rigorous public perception studies provide that evidence in a way regulators, investigators, and ethics committees can understand and audit. They also keep your risk communication honest: if spontaneous reports spark headlines, you can calibrate messaging with data on what people heard, understood, and acted upon, rather than guessing.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Signal Detection in Post-Licensure Vaccine Use

Posted on digi By digi

After licensure, millions of doses transform rare safety events from theoretical risks into observable data. A signal is a hypothesis—a statistically and clinically plausible association between a vaccine and an adverse event that warrants verification. Detecting it reliably requires a layered architecture: (1) passive spontaneous reports (e.g., national ICSRs) for early pattern recognition, (2) active denominated data (claims/EHR networks) for rate estimation, and (3) targeted follow-up for clinical adjudication. The system must connect methods to governance: a PV System Master File (PSMF), SOPs for coding/triage/escalation, and a standing multidisciplinary review (safety clinicians, epidemiologists, statisticians, quality). Documentation lives in the TMF with ALCOA discipline—attributable, legible, contemporaneous, original, accurate—so an inspector can trace any decision back to raw data and time-stamped actions.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Pharmacovigilance for COVID-19 and Future Vaccines: Methods, Thresholds, and Inspection-Ready Documentation

Posted on digi By digi

Post-marketing pharmacovigilance (PV) for COVID-19 vaccines—and for whatever comes next—requires a layered system that converts raw reports into defensible evidence. Start with intake and case processing that can scale: Individual Case Safety Reports (ICSRs) arrive via portals, email, call centers, and partner regulators. Your safety database should enforce E2B(R3) structure, MedDRA version control, and role-based access. Minimum case validity (identifiable patient, reporter, suspect product, and event) must be checked within 24 hours for seriousness triage. De-duplication rules (e.g., match on age/sex/onset/lot) are essential when media attention drives duplicate submissions. All edits and code changes must carry time-stamped audit trails consistent with Part 11/Annex 11, with ALCOA discipline visible in exported PDFs and XML acknowledgments filed to the TMF.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Designing Long-Term Vaccine Effectiveness Monitoring Programs

Posted on digi By digi

“Long-term effectiveness” (VE) is the real-world reduction in disease risk among vaccinated people compared with comparable unvaccinated (or differently vaccinated) people over extended periods—months to years. It differs from efficacy in randomized trials because exposure, variants, behaviors, and booster uptake all evolve. Sponsors and public-health programs rely on VE monitoring to answer questions randomized trials cannot: How quickly does protection wane? Which subgroups (e.g., ≥65 years, immunocompromised) lose protection first? Do boosters restore protection to prior levels and for how long? These answers inform labeling, booster recommendations, Health Care Provider (HCP) guidance, and risk–benefit summaries in periodic safety and risk-management reports.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Passive vs Active Surveillance Strategies for Post-Marketing Vaccine Safety

Posted on digi By digi

Passive surveillance collects Individual Case Safety Reports (ICSRs) from clinicians, patients, and manufacturers via national systems (e.g., VAERS/EudraVigilance analogs). It excels at early pattern recognition because it listens broadly: new Preferred Terms, atypical narratives, or demographic clustering can flag emerging issues quickly. Strengths include speed of intake, rich free-text, and relatively low cost. Limitations are well known: no direct denominators, susceptibility to under- or stimulated reporting, duplicate submissions during media spikes, and variable case quality. In passive streams, you will rely on disproportionality statistics (PRR, ROR, EBGM) to identify unusual vaccine–event reporting patterns that merit clinical review.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Using Real-World Data for Vaccine Effectiveness

Posted on digi By digi

Randomized trials establish efficacy under controlled conditions; real-world data (RWD) tell us how vaccines perform across ages, comorbidities, variants, and care systems over months or years. Post-authorization, decision makers want to know: Does protection wane? Do boosters restore it? Which subgroups (e.g., adults ≥65 years, the immunocompromised) need earlier re-dosing? RWD—immunization registries, EHR/claims, laboratory systems, and vital records—lets us answer these questions at scale. But credibility hinges on methods and documentation: explicit protocols and SAPs; auditable data pipelines; bias diagnostics (propensity scores, negative controls); and transparency about laboratory performance and manufacturing quality context. When lab results define outcomes, include analytical capability—e.g., RT-PCR LOD 25 copies/mL and LOQ 50 copies/mL (illustrative), or ELISA IgG LOD 3 BAU/mL and LOQ 10 BAU/mL—so case adjudication is reproducible. To pre-empt “non-biological” confounders in reviewer discussions, keep a short appendix with representative PDE (e.g., 3 mg/day for a residual solvent) and cleaning MACO limits (e.g., 1.0–1.2 µg/25 cm²) demonstrating stable manufacturing hygiene.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Case Study: Guillain–Barré Syndrome (GBS) Monitoring After Vaccine Launch

Posted on digi By digi

Guillain–Barré syndrome (GBS) is a rare, acute polyradiculoneuropathy characterized by rapidly progressive, symmetrical weakness and areflexia. Because true background incidence is low (typically ~1–2 per 100,000 person-years), even a small absolute excess after vaccination can matter clinically and publicly. That’s why many vaccine Risk Management Plans (RMPs) pre-specify GBS as an Adverse Event of Special Interest (AESI), with Brighton Collaboration case definitions, neurologist adjudication, and confirmatory electrophysiology. A credible post-marketing system does three things at once: (1) detects early patterns via passive reporting screens (PRR/ROR/EBGM), (2) anchors hypotheses using observed-versus-expected (O/E) counts against stratified background rates during biologically plausible risk windows (e.g., Days 0–42), and (3) confirms with self-controlled case series (SCCS) or matched cohorts that account for calendar time and confounding. Around the analytics, the Trial Master File (TMF) must make ALCOA obvious—attributable, legible, contemporaneous, original, accurate—with Part 11/Annex 11 controls and auditable code/versioning.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials

Regulatory Framework for Vaccine Post-Market Safety: A Practical Guide

Posted on digi By digi

“Regulatory framework” sounds abstract until you are the person who must file a 15-day serious unexpected case, update a Risk Management Plan (RMP), and walk an inspector through your audit trail—all in the same week. For vaccines, the framework spans law (e.g., national medicine acts; 21 CFR in the U.S.), regional guidance (EU Good Pharmacovigilance Practice—GVP), and global harmonization (ICH E-series for safety). These documents translate into practical obligations: how to collect and submit Individual Case Safety Reports (ICSRs) using ICH E2B(R3); how to code with MedDRA and de-duplicate; how to manage signals (ICH E2E) and summarize safety/benefit-risk in periodic reports (ICH E2C(R2) PBRER/PSUR). For vaccines specifically, regulators also look for active safety and effectiveness activities that complement passive reporting—observed-versus-expected (O/E) analyses, self-controlled case series (SCCS), and post-authorization effectiveness studies that inform policy.
Click to read the full article.

Post-Marketing Surveillance, Vaccine Clinical Trials